DELFI Diagnostics is a biotechnology company applying artificial intelligence and whole-genome sequencing to detect cancer early through analysis of DNA fragmentation patterns in blood. The company operates at the intersection of machine learning, fragmentomics, and liquid biopsy technologies, developing computational tools to interpret complex genomic data for diagnostic purposes.
The company's primary product, FirstLook Lung, is a non-invasive blood test designed for lung cancer screening, providing a computational alternative to traditional imaging. DELFI Diagnostics maintains a presence in Palo Alto, California, and Baltimore.
With funding exceeding $400 million, the company is building infrastructure around AI-driven analysis of whole-genome sequencing data. Its technical stack involves processing and modeling DNA fragmentation patterns - a domain requiring expertise in large-scale genomic data pipelines, machine learning model development, and bioinformatics.
